Table 2.

Most relevant radiotracers tested in clinical trials.

Targeting Molecule	Agent	Molecule Type	Tumor Model	Stage	Reference
PD-L1	[18F]BMS-986192	adnectin	NSCLC patients	clinical	[60]
	[89Zr]-labeled atezolizumab	antibody IgG1	metastatic bladder cancer, NSCLC, or triple-negative breast cancer	clinical	[61]
PD-1	[89Zr]nivolumab	antibody IgG4	NSCLC patients	clinical	[60]
CD8+	[89Zr]Df-IAB22M2C	minibody	melanoma, lung cancer, and hepatocellular carcinoma	clinical	[62]